{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:05:35Z","timestamp":1790175935445,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Indications for HSCT are increasing worldwide, paralleled by a growing demand for donors of therapeutic cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Herein, we report our real-world experience of adult HPC donor assessment during a 5-year study period (2018\u20132023): we have retrospectively revised data of 455 potential related stem cell donors, consecutively evaluated at our center. Donor medical history was assessed by a questionnaire and an interview with a trained physician experienced in donation procedures to evaluate donor fitness and medical history. Pre-existing health disorders were fully investigated. Behavioral risk factors for communicable infectious diseases were also routinely explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and discussion<\/jats:title><jats:p>Overall, 351 donors were finally assessed as eligible for HPC donation, and 233 underwent stem cell collection, 158 through apheresis from mobilized peripheral blood, and 75 through bone marrow harvest. Among them, 27 donors were selected despite the presence of pre-existing health conditions, which would be potential exclusion criteria for unrelated donors: 16 suffered from well-controlled cardiovascular diseases (CVD) and 11 from allergic diathesis. Most of the selected donors with pre-existing disorders were candidates for apheresis HPC collection (21, 77.8%), while only six (22.2%) underwent BM harvest. We then analyzed the data relative to the corresponding 233 allogeneic HSCT to explore if the presence of pre-existing diseases in the donors could show any association with transplant characteristics. Transplants from CVD and allergy donors showed no significant disparities in comparison with those from healthy donors. A significant difference emerged regarding the disease severity, with a higher proportion of patients with high\/very high disease risk index (DRI) among those receiving grafts from CVD donors (68.7% in transplants from CVD donors versus 36.0% in transplants from healthy donors, p=0.005). Multivariate analysis confirmed that high\/very high DRI patients had an increased probability of receiving donations from CVD donors (OR, 4.89; 95%CI, 1.15\u201320.86; p=0.031). Among donors with well-controlled pre-existing conditions, no adverse events were recorded during stem cell collection or at follow-up. Our results suggest that in patients at high risk for relapse requiring a prompt allogeneic transplant, a familiar donor might be accepted for HPC apheresis donation on less strict criteria than unrelated donors, without risk for both donor and patient.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1389068","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T07:53:39Z","timestamp":1717055619000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Hematopoietic stem cell transplantation: an Italian monocentric experience on the health assessment and eligibility of adult-related donors"],"prefix":"10.3389","volume":"14","author":[{"given":"Caterina Giovanna","family":"Valentini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ceglie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fatone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Metafuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Teofili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.491","article-title":"Hematopoietic stem cell transplantation: a global perspective","volume":"303","author":"Gratwohl","year":"2010","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.20","article-title":"Hematopoietic stem cell transplantation in Europe 2014: more than 40\u2009000 transplants annually","volume":"51","author":"Passweg","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.354","article-title":"Family donor care management: principles and recommendations","volume":"45","author":"van Walraven","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.34","article-title":"Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3541","article-title":"Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: A systematic review and meta-analysis","volume":"5","author":"Gagelmann","year":"2019","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bmt.2008.76","article-title":"Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health","volume":"42","author":"Sacchi","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.119","article-title":"Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT)","volume":"48","author":"Halter","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.67","article-title":"Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee","volume":"49","author":"Lown","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.08.009","article-title":"Suitability criteria for adult related donors: A consensus statement from the worldwide network for blood and marrow transplantation standing committee on donor issues","volume":"21","author":"Worel","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00184-3","article-title":"Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues","volume":"9","author":"Worel","year":"2022","journal-title":"Lancet Haematol"},{"key":"B12","volume-title":"JACIE\/FACT International Standards for Hematopoietic Cellular Therapy Product Collection, Processing and Administration. Eight Edition Version 8.2","year":"2021"},{"key":"B13","volume-title":"DECRETO 2 novembre 2015. Disposizioni relative ai requisiti di qualita' e sicurezza del sangue e degli emocomponenti. (15A09709) (GU Serie Generale n.300 del 28-12-2015 - Suppl. Ordinario n. 69)","year":"2015"},{"key":"B14","volume-title":"Italian Bone Marrow Donor Registry Standard di funzionamento del Programma nazionale italiano di donazione di Cellule Staminali Emopoietiche da non familiare. Versione XXIV","year":"2021"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000003947","article-title":"The evolution, current value, and future of the American society of anesthesiologists physical status classification system","volume":"135","author":"Horvath","year":"2021","journal-title":"Anesthesiology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu285","article-title":"New ESC\/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management","volume":"35","author":"Kristensen","year":"2014","journal-title":"Eur Heart J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000105","article-title":"2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Fleisher","year":"2014","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001179","article-title":"ABO mismatch in allogeneic hematopoietic stem cell transplant: effect on short- and long-term outcomes","volume":"7","author":"Valentini","year":"2021","journal-title":"Transplant Direct"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.12.001","article-title":"Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal","volume":"23","author":"Valentini","year":"2021","journal-title":"Cytotherapy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2021.10.005","article-title":"Validation plan of bone marrow collection, processing and distribution using the failure mode and effect analysis methodology: a technical report","volume":"24","author":"Teofili","year":"2022","journal-title":"Cytotherapy"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12834","article-title":"Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single-centre experience","volume":"114","author":"Teofili","year":"2019","journal-title":"Vox Sang"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2450\/BloodTransfus.669","article-title":"Autologous transfusion requirements in bone marrow harvest: results of the ATREMA study","volume":"22","author":"Valentini","year":"2024","journal-title":"Blood Transfus"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000301","article-title":"Updates in chronic graft-versus-host disease","volume":"2021","author":"Hamilton","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.01.007","article-title":"Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes","volume":"22","author":"Teofili","year":"2020","journal-title":"Cytotherapy"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.11.008","article-title":"Significant improvements in the practice patterns of adult related donor care in US transplantation centers","volume":"22","author":"Anthias","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30158-9","article-title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis","volume":"6","author":"Shouval","year":"2019","journal-title":"Lancet Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1537-2995.2012.03676.x","article-title":"Clinical outcomes after peripheral blood stem cell donation by related donors: a Dutch single-center cohort study","volume":"53","author":"Wiersum-Osselton","year":"2013","journal-title":"Transfusion"},{"key":"B33","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.bbmt.2018.11.004","article-title":"Effect of aging and predonation comorbidities on the related peripheral blood stem cell donor experience: report from the related donor safety study","volume":"25","author":"Pulsipher","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.200121","article-title":"Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors","volume":"104","author":"Pulsipher","year":"2019","journal-title":"Haematologica"},{"key":"B35","unstructured":"World Marrow Donor Association World marrow donor association international standards for unrelated hematopoietic stem cell donor registries2021"},{"key":"B36","unstructured":"World Marrow Donor Association WMDA international standards unrelated hematopoietic stem cell donor registries2021"},{"key":"B37","unstructured":"International standards for hematopoietic cellular therapy product collection, processing, and administration accreditation manual2021"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705137","article-title":"Adoptive transfer of vitiligo after allogeneic peripheral blood stem cell transplant","volume":"36","author":"Campbell-Fontaine","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200212000-00020","article-title":"Autoimmune thyroiditis after bone marrow transplantation in a boy with Wiskott-Aldrich syndrome","volume":"24","author":"Olivares","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78555-X","article-title":"Transfer of diabetes type 1 by bone-marrow transplantation","volume":"351","author":"Lampeter","year":"1998","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2133.1997.17821869.x","article-title":"Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity","volume":"137","author":"Snowden","year":"1997","journal-title":"Br J Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1330564","article-title":"Transmission of thyrotoxicosis of autoimmune type by sibling allogeneic bone marrow transplant","volume":"133","author":"Thomson","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.14","article-title":"Donor choice according to age for allo-SCT for AML in complete remission","volume":"48","author":"Ayuk","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.7.2043","article-title":"Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age","volume":"98","author":"Kollman","year":"2001","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.02.006","article-title":"Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most","volume":"24","author":"Shaw","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J Mol Cell Cardiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s43141-021-00205-3","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular diseases-an updated systematic review","volume":"19","author":"Senguttuvan","year":"2021","journal-title":"J Genet Eng Biotechnol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764951","article-title":"Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias","volume":"130","author":"Gibson","year":"2017","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1389068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T07:53:48Z","timestamp":1717055628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1389068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":50,"alternative-id":["10.3389\/fonc.2024.1389068"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1389068","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"article-number":"1389068"}}